Another meta-analysis by Orsini Federici et al. compared the efficacy and safety of weekly albiglutide (30-50 mg), a GLP-1 agonist, with daily sitagliptin (100 mg), a DPP-4 inhibitor, daily glimepiride (2-4 mg), a sulfonylurea, and placebo, all added to metformin in patients with T2DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.